Kelun-Biotech (06990.HK): Marketing application for a new indication of core product TROP2 ADC sac-TMT accepted by the National Medical Products Administration

Zhitong Finance APP news, Kelun-Biotech (06990.HK) announced that the marketing application for a new indication of the company's antibody-drug conjugate (ADC) targeting human trophoblast cell-surface antigen 2 (TROP2), sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (JiaTailai), has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).